Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $5.17 Consensus Target Price from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been given an average rating of “Moderate Buy” by the six brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $5.17.

SGMO has been the topic of several recent research reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Truist Financial dropped their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, April 7th. Wells Fargo & Company lowered their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Finally, StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th.

Institutional Trading of Sangamo Therapeutics

Hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in shares of Sangamo Therapeutics during the 4th quarter valued at $2,316,000. Geode Capital Management LLC increased its holdings in Sangamo Therapeutics by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company’s stock worth $2,257,000 after buying an additional 73,540 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in Sangamo Therapeutics during the fourth quarter worth about $1,744,000. Charles Schwab Investment Management Inc. raised its position in Sangamo Therapeutics by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company’s stock worth $1,162,000 after acquiring an additional 35,926 shares during the period. Finally, Two Sigma Investments LP boosted its stake in Sangamo Therapeutics by 222.1% in the fourth quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 698,296 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Stock Up 4.5 %

Shares of NASDAQ:SGMO opened at $0.75 on Thursday. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The stock’s 50 day moving average is $0.91 and its 200-day moving average is $1.39. The firm has a market capitalization of $168.64 million, a price-to-earnings ratio of -1.00 and a beta of 1.57.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. Equities research analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.